Is stem cell therapy a cure for neurologic, cardiovascular or autoimmune disease?
No. There is no version of this therapy that reverses established disease, restores lost tissue, or acts as a cure. Clinics that frame it otherwise are misleading their patients.
Response to cell therapy in complex disease is rarely dramatic. Often it's measurable. Sometimes it's absent. An honest map of what to watch, what to hope for, and what to stop hoping for.
Will stem cell therapy reverse my diagnosis?
No. No version of this therapy reverses established disease. The honest ceiling is partial, measurable modulation in the right candidate profiles.
In the right indications with reasonable candidates, the biology can modulate inflammation, support your body's own repair, and create margin where margin exists. That's the honest scope. We build on allogeneic umbilical-cord MSCs specifically because they secrete higher levels of neurotrophic, immune-modulating, and pro-repair signaling factors than other cell sources, but a richer signaling profile is still signaling, not tissue replacement.
For established structural disease, the physician team will tell you plainly what is realistic for your case. Advanced tissue loss is outside what cell signaling can address.
“Partial, measurable, gradual”
is the honest ceiling, and when it arrives, it's meaningful. Dramatic reversal narratives are not what we sell, because they are not what we see. Meaningful shifts look like incremental function gains, not reversal.
How will I know if it's working?
Follow-up calls come at 1 week, then at 1, 3 and 6 months, then once a year, and a physician joins when needed. They look at how you're doing alongside your own diary and any markers you and your doctor follow. Not day-to-day feel.
Signals that something is shifting.
-
Symptom-specific
Matched to your diagnosis: less neuropathic burning, steadier autonomic function, better exertional tolerance, or fewer inflammatory flares.
- Symptoms in your words
- Patient-kept diary
- Tracked at 1, 3 and 6 months, then yearly
-
Functional
Walking tolerance, fine-motor tasks, sleep quality. Function often moves before symptoms change dramatically.
- Walking distance
- Activity re-introduction
- Sleep quality
-
Objective
Where applicable, nerve conduction, imaging metrics, inflammatory markers, from tests you and your own doctor follow.
- NCV when indicated
- Your own labs, passed to the medical team
- Imaging your own doctor repeats
Non-response is real.
Some patients show real response. A meaningful minority don't. We're straight about both.
A meaningful minority of even well-screened complex-disease candidates see no measurable response at nine months. We structure follow-up to identify that, not to paper over it.
When a case isn't responding, the next conversation is about what that means, what alternatives exist, and whether any further intervention from us has rationale. That's decided at review.
Response window: months 3 to 9. Complex disease remodels slowly. The response curve is longer than joint or IV cases.
-
Month 3
Early read
Baseline comparison. Response too early to be conclusive. Continue structured follow-up.
-
Month 6
Mid-window
First meaningful read on response direction. Adjust follow-up plan accordingly.
-
Month 12
Definitive read
Response is what it's going to be. Decision point on maintenance, trial enrollment, or stopping.
Is another session worth trying if the first doesn't respond?
Sometimes. The rationale for a second intervention has to be biologically coherent, not hope-driven. That's decided at review, and if the rationale isn't there, we'll say so.
Ask what is realistic for your case.
If you're comfortable with “partial, measurable, gradual” as the ceiling, and you meet the candidacy profile, submit for evaluation.
Not medical advice. Individual results vary. Every candidacy undergoes careful screening.